Navigation Links
INTAC™ Technology Combats Misuse of Extended Release Drugs
Date:5/15/2012

BEDMINSTER, N.J., May 15, 2012 /PRNewswire/ -- During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012 • Honolulu, HI) Grunenthal will present results from clinical studies utilizing a product based on its INTAC™ formulation technology. INTAC™ is designed to be crush-resistant and to protect intended action of extended release drugs. Applying INTAC™ to prescription opioid drugs is considered an efficient means to combat unintended and intended drug misuse and abuse through tampering with the formulation.

Prescription opioids are at the center of a major public health crisis of misuse and abuse in the United States. Prescription drug abuse is the fastest-growing drug problem in the US and drug overdose death rates have risen steadily in the US[1]. Technological approaches that intend to prohibit or reduce the ability to abuse specific time-release drugs by tampering with the formulation through crushing are therefore an effective means to address the issue.

Dr. Hans-Jurgen Stahlberg, Director and International Clinical Lead at Grunenthal will present data from a clinical development program aimed at demonstrating bioequivalence between a non-tamper resistant originator product and the product utilizing INTAC™ formulation technology (Bridging from Conventional Marketed Extended Release Formulations to New Tamper Resistant Alternatives, poster # 391). The structure and regulatory frame for the study program as well as the results and outcome for physicians and patients will be discussed.

About INTAC™

INTAC™, Grunenthal's tamper resistant formulation technology, is designed to deter various relevant routes of abuse / inadvertent misuse from tablet tampering by imposing a specific mechanical stability to the tablet. This mechanical stability is created by the combination of specific excipients together with a unique manufacturing process. Grunenthal's proprietary INTAC™ approach is established at commercial manufacturing scale and is featured in FDA-approved products which are marketed by US partners. Grunenthal considers its patent protected INTAC™ to be the leading technology for abuse-deterrent and tamper-resistant opioid products. The INTAC™ technology is available for licensing to interested companies for various product opportunities.

About Grunenthal

The Grunenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company to be a leader in therapy innovation. Grunenthal is one of the last five research-oriented pharmaceutical corporations with headquarters based in Germany which sustainably invests in research and development. These investments amounted to about 25 % of revenues in 2011. Grunenthal's research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grunenthal Group has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and approx. 4200 employees are working for the Grunenthal Group worldwide. In 2011, Grunenthal reached estimated revenues of 947 Mio euros. More information: www.grunenthal.com.

[1] Epidemic: Responding to America's Prescription Drug Abuse Crisis. Executive Office of the President of the United States, 2011


'/>"/>
SOURCE Grünenthal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
2. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
3. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
4. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
5. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
9. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
Breaking Medicine Technology:
(Date:5/5/2016)... California (PRWEB) , ... May 05, 2016 , ... ... importance of sunshine to human health, today GrassrootsHealth, a public health promotion and ... from an agrarian to a technology-driven society, and other shifts in cultural behavior ...
(Date:5/5/2016)... Wisconsin (PRWEB) , ... May 05, 2016 , ... ... proud to announce that Dr. Julie Lombardo, PT, DPT, MA, OCS, WCS, has ... of the WPTA Private Practice Award. The WPTA Private Practice Award is awarded ...
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... “Less than ... Jeffers, Little City Executive Director. “As one of ten non-profit organizations to participate and ... Points of Light. The ultimate benefit is that for every $1 we invest in ...
(Date:5/4/2016)... Boulder, CO (PRWEB) , ... May 04, 2016 ... ... variety of observational and interview techniques, seeks to add a deeper understanding of ... have strengths and weaknesses, and each answers different yet important questions. , In ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a provider ... its innovative Secure Messaging platform, which includes secure, private messaging, large file sharing, ... Cirius’s portfolio of patents around innovative features for securing, tracking, and controlling messages ...
Breaking Medicine News(10 mins):